PE20241784A1 - Composiciones y metodos para el tratamiento de la depresion - Google Patents

Composiciones y metodos para el tratamiento de la depresion

Info

Publication number
PE20241784A1
PE20241784A1 PE2023003004A PE2023003004A PE20241784A1 PE 20241784 A1 PE20241784 A1 PE 20241784A1 PE 2023003004 A PE2023003004 A PE 2023003004A PE 2023003004 A PE2023003004 A PE 2023003004A PE 20241784 A1 PE20241784 A1 PE 20241784A1
Authority
PE
Peru
Prior art keywords
methods
depression
compositions
treatment
relates
Prior art date
Application number
PE2023003004A
Other languages
English (en)
Spanish (es)
Inventor
Vanina Popova
Adam Savitz
Rama Melkote
Wayne C Drevets
Srihari Gopal
Darrel Pemberton
Chakradhar Lagishetty
Iva Kezic
Mark Schmidt
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/307,858 external-priority patent/US11266627B1/en
Priority claimed from US17/670,123 external-priority patent/US12161622B2/en
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of PE20241784A1 publication Critical patent/PE20241784A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
PE2023003004A 2021-05-04 2022-05-03 Composiciones y metodos para el tratamiento de la depresion PE20241784A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17/307,858 US11266627B1 (en) 2021-05-04 2021-05-04 Compositions and methods for the treatment of depression
US17/670,123 US12161622B2 (en) 2021-05-04 2022-02-11 Compositions and methods for the treatment of depression
US202263313792P 2022-02-25 2022-02-25
PCT/IB2022/054085 WO2022234457A1 (en) 2021-05-04 2022-05-03 Compositions and methods for the treatment of depression

Publications (1)

Publication Number Publication Date
PE20241784A1 true PE20241784A1 (es) 2024-09-06

Family

ID=81654924

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023003004A PE20241784A1 (es) 2021-05-04 2022-05-03 Composiciones y metodos para el tratamiento de la depresion

Country Status (16)

Country Link
EP (1) EP4333835A1 (https=)
JP (1) JP2024516297A (https=)
KR (1) KR20240004857A (https=)
AU (1) AU2022268720A1 (https=)
BR (1) BR112023023030A2 (https=)
CA (1) CA3219079A1 (https=)
CL (1) CL2023003259A1 (https=)
CO (1) CO2023015571A2 (https=)
IL (1) IL308221A (https=)
JO (1) JOP20230276A1 (https=)
MX (1) MX2023013040A (https=)
PE (1) PE20241784A1 (https=)
PH (1) PH12023552963A1 (https=)
TW (1) TW202313003A (https=)
UY (1) UY39754A (https=)
WO (1) WO2022234457A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2023231493A1 (en) * 2022-03-07 2024-10-24 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
WO2024216046A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating anhedonia
WO2024216061A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト

Also Published As

Publication number Publication date
CO2023015571A2 (es) 2023-11-30
EP4333835A1 (en) 2024-03-13
IL308221A (en) 2024-01-01
CL2023003259A1 (es) 2024-05-31
WO2022234457A1 (en) 2022-11-10
PH12023552963A1 (en) 2024-03-11
MX2023013040A (es) 2024-01-05
UY39754A (es) 2022-11-30
JP2024516297A (ja) 2024-04-12
KR20240004857A (ko) 2024-01-11
AU2022268720A1 (en) 2023-12-21
TW202313003A (zh) 2023-04-01
BR112023023030A2 (pt) 2024-02-15
CA3219079A1 (en) 2022-11-10
JOP20230276A1 (ar) 2023-11-02

Similar Documents

Publication Publication Date Title
PE20241784A1 (es) Composiciones y metodos para el tratamiento de la depresion
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
UY28041A1 (es) Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial.
MX367541B (es) Inhibidores de papd5 y papd7 para tratar la infeccion por hepatitis b.
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
EA202091597A1 (ru) Способы и композиции для лечения апноэ сна
CO6361942A2 (es) Terapia de combinacion con epoxicetonas peptidicas
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
DE60200492D1 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
AR047719A1 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
BR9911049A (pt) Terapia combinada para tratamento de depressão resistente
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
ECSP11011029A (es) Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional.
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
MX2024008618A (es) Composiciones y métodos para el tratamiento de la depresión.
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
AR125762A1 (es) Composiciones y métodos para el tratamiento de la depresión
MX2024007227A (es) Psilocibina y un inhibidor de la recaptación de serotonina complementario para usar en el tratamiento de la depresión resistente al tratamiento.
BRPI0413726A (pt) combinação de inibidores da recaptação de serotonina e inibidores da recaptação de norepinefrina
MX2024008619A (es) Composiciones y métodos para el tratamiento de la depresión.
AR127946A1 (es) ESTIMULADOR TREG SELECTIVO RUR₂₀ₖD-IL-2 Y COMPOSICIONES RELACIONADAS
GEAP202416526A (en) Treatment of major depressive disorder